{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T09:34:46Z","timestamp":1786700086370,"version":"build-2736575974"},"reference-count":24,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr. Oncol.","Current Oncology"],"abstract":"<jats:p>Background: Identifying biomarkers for biological vulnerability in older patients with cancer remains challenging. We evaluated psoas muscle index (PMI) and immunonutritional indices\u2019 association with toxicity and overall survival (OS) in patients \u2265 65 years receiving immune checkpoint inhibitors (ICIs). Methods: This retrospective study included 104 patients. Baseline sarcopenia was assessed via CT-derived PMI at the L3 level. Immunonutritional status was evaluated using the Prognostic Nutritional Index (PNI). Primary endpoint was immune-related adverse event (irAE) development; secondary endpoint was OS. Results: Median age was 71 years. Patients developing irAEs had significantly higher baseline PNI than those without (49.0 vs. 46.0, p = 0.042). OS did not differ significantly by irAE status (p = 0.859) or PMI group (p = 0.664). However, low PNI was strongly associated with poorer OS (17.0 months vs. not reached, p &lt; 0.001). In a multivariable Cox model stratified by ICI treatment type, higher PNI remained independently associated with better OS (adjusted HR: 0.86, 95% CI: 0.81\u20130.93, p &lt; 0.001). PNI correlated negatively with inflammatory markers NLR and SII. Conclusions: Baseline PNI was independently associated with OS, whereas PMI was not significantly associated with survival in this cohort. These findings support the potential prognostic utility of PNI in older patients receiving immunotherapy but should not be interpreted as demonstrating superiority over comprehensive sarcopenia assessment.<\/jats:p>","DOI":"10.3390\/curroncol33080480","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T08:08:29Z","timestamp":1786694909000},"page":"480","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic Value of Immunonutritional Status and Radiologic Muscle Mass in Older Patients Receiving Immune Checkpoint Inhibitors: A Real-World Study"],"prefix":"10.3390","volume":"33","author":[{"given":"H\u00fclya","family":"Erta\u015f","sequence":"first","affiliation":[{"name":"Medical Oncology, Ali Osman Sonmez Oncology Hospital, Bursa 16000, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burcu","family":"Caner","sequence":"additional","affiliation":[{"name":"Medical Oncology, Ataturk State Hospital, Aydin 09020, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibel","family":"Oyucu Orhan","sequence":"additional","affiliation":[{"name":"Medical Oncology, Bursa City Hospital, Bursa 16110, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Buket","family":"\u015eahin \u00c7elik","sequence":"additional","affiliation":[{"name":"Medical Oncology, Ali Osman Sonmez Oncology Hospital, Bursa 16000, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I\u015f\u0131l","family":"Y\u00fcce\u0131\u015f\u0131k","sequence":"additional","affiliation":[{"name":"Radiology, Bursa City Hospital, Bursa 16110, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4666-9930","authenticated-orcid":false,"given":"Yasemin","family":"Ko\u00e7","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Institute of Health Sciences, Ankara University, Ankara 06230, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1007\/s11912-024-01528-3","article-title":"Immune Checkpoint Inhibitors in Geriatric Oncology","volume":"26","author":"Cook","year":"2024","journal-title":"Curr. Oncol. Rep."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.cpt.2023.08.001","article-title":"Impact of immunosenescence and inflammaging on the effects of immune checkpoint inhibitors","volume":"2","author":"Hou","year":"2023","journal-title":"Cancer Pathog. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/s41573-024-01126-9","article-title":"Enhancing immunity during ageing by targeting interactions within the tissue environment","volume":"24","author":"Bracken","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1038\/s41568-025-00858-z","article-title":"Ageing, immune fitness and cancer","volume":"25","author":"Dolan","year":"2025","journal-title":"Nat. Rev. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1200\/JCO.2018.78.8687","article-title":"Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology","volume":"36","author":"Mohile","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"104259","DOI":"10.1016\/j.critrevonc.2024.104259","article-title":"Geriatric predictors of response and adverse events in older patients with cancer treated with immune checkpoint inhibitors: A systematic review","volume":"194","author":"Mooijaart","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/ageing\/afz046","article-title":"Sarcopenia: Revised European consensus on definition and diagnosis","volume":"48","author":"Bahat","year":"2019","journal-title":"Age Ageing"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s40266-025-01252-y","article-title":"Sarcopenia and Cachexia in Older Patients with Cancer: Pathophysiology, Diagnosis, Impact on Outcomes, and Management Strategies","volume":"42","author":"Papadopoulos","year":"2025","journal-title":"Drugs Aging"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1001\/jamaoncol.2018.0137","article-title":"Association of Muscle and Adiposity Measured by Computed Tomography with Survival in Patients with Nonmetastatic Breast Cancer","volume":"4","author":"Caan","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1002\/jcsm.12755","article-title":"Predictive impact of sarcopenia in solid cancers treated with immune checkpoint inhibitors: A meta-analysis","volume":"12","author":"Takenaka","year":"2021","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1038\/s41598-019-39120-6","article-title":"Impact of sarcopenia in patients with advanced non-small cell lung cancer treated with PD-1 inhibitors: A preliminary retrospective study","volume":"9","author":"Shiroyama","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Ma, W., Shi, Q., Zhang, L., Qiu, Z., Kuang, T., Zhao, K., and Wang, W. (2024). Impact of baseline body composition on prognostic outcomes in urological malignancies treated with immunotherapy: A pooled analysis of 10 retrospective studies. BMC Cancer, 24.","DOI":"10.1186\/s12885-024-12579-x"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Al-Danakh, A., Safi, M., Jian, Y., Yang, L., Zhu, X., Chen, Q., Yang, K., Wang, S., Zhang, J., and Yang, D. (2024). Aging-related biomarker discovery in the era of immune checkpoint inhibitors for cancer patients. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1348189"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Ni, L., Huang, J., Ding, J., Kou, J., Shao, T., Li, J., Gao, L., Zheng, W., and Wu, Z. (2022). Prognostic Nutritional Index Predicts Response and Prognosis in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. Front. Nutr., 9.","DOI":"10.3389\/fnut.2022.823087"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Wang, Y., Lei, Y., Zheng, D., Yang, Y., Luo, L., Li, J., and Xie, X. (2024). Prognostic value of lung immune prognostic index in non-small cell lung cancer patients receiving immune checkpoint inhibitors: A meta-analysis. Pathol. Oncol. Res., 30.","DOI":"10.3389\/pore.2024.1611773"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1038\/s41598-020-58498-2","article-title":"Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1\/PD-L1 checkpoint inhibitors: A multicenter real-life study","volume":"10","author":"Cortellini","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1017\/S0029665118000046","article-title":"A window beneath the skin: How computed tomography assessment of body composition can assist in the identification of hidden wasting conditions in oncology that profoundly impact outcomes","volume":"77","author":"Daly","year":"2018","journal-title":"Proc. Nutr. Soc."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2217\/fon.09.136","article-title":"Role of systemic inflammatory response in predicting survival in patients with primary operable cancer","volume":"6","author":"Roxburgh","year":"2010","journal-title":"Future Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.lungcan.2019.08.006","article-title":"Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors","volume":"136","author":"Shoji","year":"2019","journal-title":"Lung Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1248\/bpb.b23-00760","article-title":"Association between the Prognostic Nutritional Index and the Occurrence of Immune-Related Adverse Events","volume":"47","author":"Furuno","year":"2024","journal-title":"Biol. Pharm. Bull."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e2352302","DOI":"10.1001\/jamanetworkopen.2023.52302","article-title":"Immune-Related Adverse Events and Survival Among Patients with Metastatic NSCLC Treated with Immune Checkpoint Inhibitors","volume":"7","author":"Cook","year":"2024","journal-title":"JAMA Netw. Open."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e70261","DOI":"10.1111\/1759-7714.70261","article-title":"Association of Immune-Related Adverse Events and the Efficacy of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Adjusting for Immortal Time Bias","volume":"17","author":"Kuwabara","year":"2026","journal-title":"Thorac. Cancer"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/8\/480\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T08:59:01Z","timestamp":1786697941000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/8\/480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":24,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["curroncol33080480"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33080480","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,14]]}}}